DK3324932T3 - COMPOSITIONS AND METHODS FOR NANOPARTICLE LYOFILE FORMS - Google Patents

COMPOSITIONS AND METHODS FOR NANOPARTICLE LYOFILE FORMS Download PDF

Info

Publication number
DK3324932T3
DK3324932T3 DK16828602.9T DK16828602T DK3324932T3 DK 3324932 T3 DK3324932 T3 DK 3324932T3 DK 16828602 T DK16828602 T DK 16828602T DK 3324932 T3 DK3324932 T3 DK 3324932T3
Authority
DK
Denmark
Prior art keywords
lyofile
nanoparticle
compositions
methods
forms
Prior art date
Application number
DK16828602.9T
Other languages
Danish (da)
Inventor
Wenbin Ying
Roger Adami
Liping Wang
Dong Liu
Haiqing Yin
Yuwei Wang
Original Assignee
Nitto Denko Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nitto Denko Corp filed Critical Nitto Denko Corp
Application granted granted Critical
Publication of DK3324932T3 publication Critical patent/DK3324932T3/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/513Organic macromolecular compounds; Dendrimers
    • A61K9/5161Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/713Double-stranded nucleic acids or oligonucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/5123Organic compounds, e.g. fats, sugars
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111General methods applicable to biologically active non-coding nucleic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering N.A.
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00Applications; Uses
    • C12N2320/30Special therapeutic applications
    • C12N2320/32Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK16828602.9T 2015-07-22 2016-07-22 COMPOSITIONS AND METHODS FOR NANOPARTICLE LYOFILE FORMS DK3324932T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562195356P 2015-07-22 2015-07-22
PCT/US2016/043537 WO2017015552A1 (en) 2015-07-22 2016-07-22 Compositions and methods for nanoparticle lyophile forms

Publications (1)

Publication Number Publication Date
DK3324932T3 true DK3324932T3 (en) 2021-04-06

Family

ID=57834582

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16828602.9T DK3324932T3 (en) 2015-07-22 2016-07-22 COMPOSITIONS AND METHODS FOR NANOPARTICLE LYOFILE FORMS

Country Status (23)

Country Link
US (3) US10300018B2 (en)
EP (1) EP3324932B1 (en)
JP (2) JP6875373B2 (en)
KR (1) KR20180030698A (en)
CN (2) CN108024957B (en)
AU (1) AU2016297153B2 (en)
BR (1) BR112018001178A2 (en)
CA (1) CA2992849C (en)
CY (1) CY1123984T1 (en)
DK (1) DK3324932T3 (en)
EA (1) EA035761B1 (en)
ES (1) ES2862191T3 (en)
HR (1) HRP20210523T1 (en)
HU (1) HUE053990T2 (en)
IL (2) IL288342B2 (en)
LT (1) LT3324932T (en)
MX (1) MX2018000891A (en)
PL (1) PL3324932T3 (en)
PT (1) PT3324932T (en)
RS (1) RS61607B1 (en)
SI (1) SI3324932T1 (en)
TW (1) TWI732773B (en)
WO (1) WO2017015552A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3324932T3 (en) * 2015-07-22 2021-07-05 Nitto Denko Corporation Compositions and methods for nanoparticle lyophile forms
WO2019116062A1 (en) 2017-12-12 2019-06-20 Lead Biotherapeutics Ltd. Solid lipid nanoparticle for intracellular release of active substances and method for production the same
CN108813619A (en) * 2018-07-19 2018-11-16 广州市汉廷食品有限公司 A kind of pollution-free food additive and its preparation process
US20210324002A1 (en) 2018-09-28 2021-10-21 Nutcracker Therapeutics, Inc. Tertiary amino lipidated cationic peptides for nucleic acid delivery
WO2020102668A1 (en) * 2018-11-16 2020-05-22 Nitto Denko Corporation Rna interference delivery formulation and methods for malignant tumors
WO2021060440A1 (en) * 2019-09-26 2021-04-01 日油株式会社 Lipid nanoparticle lyophilized composition
BR112023002642A2 (en) * 2020-08-14 2023-04-04 Arcturus Therapeutics Inc METHOD FOR LYOPHYLIZING LIPID NANOPARTICLES
EP4416287A1 (en) 2021-10-14 2024-08-21 Hemoshear Therapeutics, Inc. Compositions and methods of treating diseases associated with bile acid transporter
CN116643056A (en) * 2022-02-15 2023-08-25 厦门万泰凯瑞生物技术有限公司 Thyroid stimulating hormone receptor complex, kit, preparation method and application
US20240254485A1 (en) 2023-01-13 2024-08-01 Hemoshear Therapeutics, Inc. Sirnas targeting slc10a1 transcripts, compositions and uses thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4537683A (en) 1982-02-01 1985-08-27 Rohm And Haas Company Trihalomethane precursor removal using ion exchange emulsions
US4537883A (en) * 1982-11-12 1985-08-27 Mead Johnson & Company Lyophilized cyclophosphamide
US4927571A (en) 1987-05-18 1990-05-22 Liposome Technology, Inc. Preparation of injectable doxorubicin/liposome suspension
US20040121983A1 (en) * 2002-08-12 2004-06-24 Council Of Scientific And Industrial Research Method for treating leishmaniasis using methyl-beta-cyclodextrin
PT2277551E (en) * 2002-09-06 2013-08-22 Cerulean Pharma Inc Cyclodextrin-based polymers for delivering the therapeutic agents covalently bound thereto
CA2528411C (en) 2003-06-04 2012-09-04 Georgetown University Method for improving stability and shelf-life of liposome complexes
WO2006050327A2 (en) 2004-10-28 2006-05-11 Alza Corporation Lyophilized liposome formulations and method
CA2587337A1 (en) 2004-11-19 2006-05-26 Novosom Ag Improvements in or relating to pharmaceutical compositions for local administration
JP5334170B2 (en) * 2007-02-09 2013-11-06 国立大学法人 奈良先端科学技術大学院大学 C70-containing liposome, method for producing the same, and use thereof
JP5891175B2 (en) * 2009-12-11 2016-03-22 バインド セラピューティックス インコーポレイテッド Stable formulation against lyophilization of therapeutic particles
WO2011103150A2 (en) 2010-02-18 2011-08-25 Cephalon, Inc. Lyophilized preparations of bendamustine
US20110237686A1 (en) * 2010-03-26 2011-09-29 Cerulean Pharma Inc Formulations and methods of use
CN102018672B (en) * 2010-11-29 2013-09-18 广州朗圣药业有限公司 Freeze-dried liposome composition of water-soluble medicament and preparation method thereof
EP3674292B1 (en) * 2011-06-08 2024-04-10 Translate Bio, Inc. Cleavable lipids
US9011903B2 (en) 2011-06-08 2015-04-21 Nitto Denko Corporation Cationic lipids for therapeutic agent delivery formulations
CN104114156A (en) 2011-10-21 2014-10-22 切拉托尔制药公司 Lyophilized liposomes
US9579338B2 (en) * 2011-11-04 2017-02-28 Nitto Denko Corporation Method of producing lipid nanoparticles for drug delivery
PL2773326T3 (en) 2011-11-04 2019-06-28 Nitto Denko Corporation Method for sterilely producing lipid-nucleic acid particles
US9554999B2 (en) 2012-03-28 2017-01-31 Windtree Therapeutics, Inc. Lyophilization of synthetic liposomal pulmonary surfactant
CN104487055A (en) * 2012-03-29 2015-04-01 夏尔人类遗传性治疗公司 Lipid-derived neutral nanoparticles
EP3489220B9 (en) 2012-06-08 2021-11-10 Nitto Denko Corporation Lipids for therapeutic agent delivery formulations
US20140271815A1 (en) 2013-03-15 2014-09-18 Aryo Sorayya Heat-and freeze-stable vaccines and methods of making and using same
PL3324932T3 (en) * 2015-07-22 2021-07-05 Nitto Denko Corporation Compositions and methods for nanoparticle lyophile forms

Also Published As

Publication number Publication date
TW201717914A (en) 2017-06-01
CY1123984T1 (en) 2022-05-27
IL288342B2 (en) 2024-02-01
EP3324932A1 (en) 2018-05-30
SI3324932T1 (en) 2021-07-30
US10300018B2 (en) 2019-05-28
MX2018000891A (en) 2018-06-11
LT3324932T (en) 2021-04-26
JP2021119161A (en) 2021-08-12
IL288342B1 (en) 2023-10-01
CN113679689A (en) 2021-11-23
JP2018521083A (en) 2018-08-02
US11737982B2 (en) 2023-08-29
WO2017015552A1 (en) 2017-01-26
EP3324932A4 (en) 2019-03-06
PT3324932T (en) 2021-04-06
CA2992849C (en) 2023-06-13
TWI732773B (en) 2021-07-11
AU2016297153B2 (en) 2021-02-25
IL288342A (en) 2022-01-01
CN108024957A (en) 2018-05-11
BR112018001178A2 (en) 2018-09-11
IL257029B (en) 2021-12-01
IL257029A (en) 2018-03-29
ES2862191T3 (en) 2021-10-07
EA035761B1 (en) 2020-08-06
AU2016297153A1 (en) 2018-03-01
US20190231695A1 (en) 2019-08-01
JP6875373B2 (en) 2021-05-26
CN108024957B (en) 2021-08-24
HRP20210523T1 (en) 2021-05-14
CN113679689B (en) 2023-09-01
US20170020819A1 (en) 2017-01-26
KR20180030698A (en) 2018-03-23
EA201890367A1 (en) 2018-06-29
JP7268079B2 (en) 2023-05-02
CA2992849A1 (en) 2017-01-26
US20240000710A1 (en) 2024-01-04
RS61607B1 (en) 2021-04-29
PL3324932T3 (en) 2021-07-05
EP3324932B1 (en) 2021-03-10
HUE053990T2 (en) 2021-08-30

Similar Documents

Publication Publication Date Title
HK1257295A1 (en) Compositions and methods for immunooncology
DK3443009T3 (en) ANTI-HOUR-3 ANTIBODIES AND COMPOSITIONS
DK3495023T3 (en) SEMIFLUOROIATED COMPOUNDS AND COMPOSITIONS THEREOF
DK3316909T3 (en) ANTI-NTB-A ANTIBODIES AND RELATED COMPOSITIONS AND METHODS
DK3888658T3 (en) EIF4-A INHIBITING COMPOUNDS AND METHODS RELATED THEREOF
DK3215147T3 (en) NEUROTENANT NORKETAMINE COMPOUNDS AND METHODS
DK3092256T3 (en) COMPOUNDS AND COMPOSITIONS FOR IMMUNTERAPHY
DK3169741T3 (en) IMPROVED BINDER COMPOSITIONS AND USES THEREOF
DK3145493T3 (en) METHODS AND COMPOSITIONS RELATING TO EXOSOMES
KR20180084891A (en) Structural compositions and methods
BR112017013838A2 (en) nanoparticle compositions and methods for immunotherapy
DK3008168T3 (en) SC-CELLS AND COMPOSITIONS AND PROCEDURE FOR CREATING THEREOF
DK3218358T3 (en) IFLUOROMETHYL-AMINOPYRIDINES AND DIFLUOROMETHYL-AMINOPYRIMIDINES
DK3015526T3 (en) HYDROFLUOROLEFIN-BASED COMPOSITION AND USE
DK3324932T3 (en) COMPOSITIONS AND METHODS FOR NANOPARTICLE LYOFILE FORMS
DK3102200T3 (en) Therapeutic compound and composition
DK3233192T3 (en) COMPOSITIONS AND METHODS FOR TARGETED CYTOKIN SUBMISSION
DK3200815T3 (en) METHODS AND COMPOSITIONS FOR TREATING CANCER
DK3194564T3 (en) TRICHODERMA COMPOSITIONS AND METHODS OF APPLICATION
DK3265641T3 (en) RISK AND PROCEDURE
DK3212776T3 (en) BETA-GLUCOSIDASE COMPOSITIONS AND METHODS
DK3110446T3 (en) Methods and compositions for treating Siglec-8-associated diseases
DE112015003457A5 (en) Al-cast alloy
DK3288379T3 (en) PEPTIME COMPOSITIONS AND METHODS OF APPLICATION
DK3386956T3 (en) FUMAGILLOLD DERIVATIVES AND POLYMORPHES THEREOF